现实世界中HR+/HER2-晚期乳腺癌患者既往抗癌治疗与帕博西尼临床结果的关系

IF 4.4 3区 医学 Q2 ONCOLOGY
Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z Montelongo, Zhe Zhang, Eric Gauthier, Debu Tripathy
{"title":"现实世界中HR+/HER2-晚期乳腺癌患者既往抗癌治疗与帕博西尼临床结果的关系","authors":"Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z Montelongo, Zhe Zhang, Eric Gauthier, Debu Tripathy","doi":"10.1007/s11523-025-01158-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In the real-world POLARIS study, patients with hormone receptor-positive (HR<sup>+</sup>)/human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) advanced/metastatic breast cancer (ABC) who had received palbociclib + endocrine therapy (ET) had a median real-world progression-free survival (rwPFS) of 20.9 months in the first line of therapy (1LOT) and 13.5 months in second or later LOTs (≥ 2LOT).</p><p><strong>Objective: </strong>The aim of this study is to assess the relationship of prior anticancer treatments with clinical outcomes.</p><p><strong>Patients and methods: </strong>Kaplan-Meier estimates of rwPFS and overall survival (OS) are described by prior anticancer treatments in patients with HR<sup>+</sup>/HER2<sup>-</sup> ABC who received palbociclib + ET.</p><p><strong>Results: </strong>A total of 1250 patients received ≥ 1 palbociclib dose (1LOT: 901 [72.1%]; ≥ 2LOT: 349 [27.9%]). In the 1LOT group, 563 (62.5%) had received prior (neo)adjuvant treatments: 24.3% ET alone, 26.6% chemotherapy alone, 45.5% ET + chemotherapy, and 3.6% other treatments; both median rwPFS and OS were numerically longer in patients who had received ET alone (30.4 months and not reached, respectively) and had had no prior treatment (23.7 and 53.3 months, respectively) than in patients with prior chemotherapy alone (15.9 and 38.4 months, respectively). In the ≥ 2LOT group, patients with prior ET alone (21.5%; 19.8 months) or chemotherapy alone (16.6%; 15.5 months) in the (neo)adjuvant and/or metastatic setting had numerically longer median rwPFS than those with prior ET + chemotherapy (41.3%; 11.6 months); OS was comparable regardless of prior treatment.</p><p><strong>Conclusions: </strong>Patients with HR<sup>+</sup>/HER2<sup>-</sup> ABC who had received ET alone prior to palbociclib tended to have better clinical outcomes, while those with prior chemotherapy had less clinical benefit.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT03280303.</p>","PeriodicalId":22195,"journal":{"name":"Targeted Oncology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer in Real-World Settings.\",\"authors\":\"Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z Montelongo, Zhe Zhang, Eric Gauthier, Debu Tripathy\",\"doi\":\"10.1007/s11523-025-01158-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In the real-world POLARIS study, patients with hormone receptor-positive (HR<sup>+</sup>)/human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) advanced/metastatic breast cancer (ABC) who had received palbociclib + endocrine therapy (ET) had a median real-world progression-free survival (rwPFS) of 20.9 months in the first line of therapy (1LOT) and 13.5 months in second or later LOTs (≥ 2LOT).</p><p><strong>Objective: </strong>The aim of this study is to assess the relationship of prior anticancer treatments with clinical outcomes.</p><p><strong>Patients and methods: </strong>Kaplan-Meier estimates of rwPFS and overall survival (OS) are described by prior anticancer treatments in patients with HR<sup>+</sup>/HER2<sup>-</sup> ABC who received palbociclib + ET.</p><p><strong>Results: </strong>A total of 1250 patients received ≥ 1 palbociclib dose (1LOT: 901 [72.1%]; ≥ 2LOT: 349 [27.9%]). In the 1LOT group, 563 (62.5%) had received prior (neo)adjuvant treatments: 24.3% ET alone, 26.6% chemotherapy alone, 45.5% ET + chemotherapy, and 3.6% other treatments; both median rwPFS and OS were numerically longer in patients who had received ET alone (30.4 months and not reached, respectively) and had had no prior treatment (23.7 and 53.3 months, respectively) than in patients with prior chemotherapy alone (15.9 and 38.4 months, respectively). In the ≥ 2LOT group, patients with prior ET alone (21.5%; 19.8 months) or chemotherapy alone (16.6%; 15.5 months) in the (neo)adjuvant and/or metastatic setting had numerically longer median rwPFS than those with prior ET + chemotherapy (41.3%; 11.6 months); OS was comparable regardless of prior treatment.</p><p><strong>Conclusions: </strong>Patients with HR<sup>+</sup>/HER2<sup>-</sup> ABC who had received ET alone prior to palbociclib tended to have better clinical outcomes, while those with prior chemotherapy had less clinical benefit.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT03280303.</p>\",\"PeriodicalId\":22195,\"journal\":{\"name\":\"Targeted Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Targeted Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11523-025-01158-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11523-025-01158-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在现实世界的POLARIS研究中,接受帕博西尼+内分泌治疗(ET)的激素受体阳性(HR+)/人表皮生长因子受体2阴性(HER2-)晚期/转移性乳腺癌(ABC)患者的中位真实世界无进展生存期(rwPFS)在一线治疗(1LOT)中为20.9个月,在二线或后续治疗(≥2LOT)中为13.5个月。目的:本研究的目的是评估既往抗癌治疗与临床结果的关系。患者和方法:HR+/HER2- ABC患者接受帕博西尼+ et的既往抗癌治疗描述了rwPFS和总生存期(OS)的Kaplan-Meier估计。结果:共有1250例患者接受了≥1剂量的帕博西尼(1LOT: 901 [72.1%];≥2lot: 349[27.9%])。在1LOT组中,563例(62.5%)患者先前接受过(neo)辅助治疗:24.3%的患者单独接受ET治疗,26.6%的患者单独接受化疗,45.5%的患者接受ET +化疗,3.6%的患者接受其他治疗;单独接受ET治疗的患者(分别为30.4个月和未达到)和没有接受过治疗的患者(分别为23.7个月和53.3个月)的中位rwPFS和OS均比单独接受化疗的患者(分别为15.9个月和38.4个月)更长。在≥2LOT组中,仅有ET病史的患者(21.5%;19.8个月)或单独化疗(16.6%;15.5个月)在(新)辅助和/或转移情况下的中位rwPFS比先前接受ET +化疗的患者(41.3%;11.6个月);无论之前的治疗如何,OS具有可比性。结论:HR+/HER2- ABC患者在帕博西尼之前单独接受ET治疗往往具有更好的临床结果,而先前接受化疗的患者临床获益较少。试验注册:ClinicalTrials.gov, NCT03280303。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR+/HER2- Advanced Breast Cancer in Real-World Settings.

Background: In the real-world POLARIS study, patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced/metastatic breast cancer (ABC) who had received palbociclib + endocrine therapy (ET) had a median real-world progression-free survival (rwPFS) of 20.9 months in the first line of therapy (1LOT) and 13.5 months in second or later LOTs (≥ 2LOT).

Objective: The aim of this study is to assess the relationship of prior anticancer treatments with clinical outcomes.

Patients and methods: Kaplan-Meier estimates of rwPFS and overall survival (OS) are described by prior anticancer treatments in patients with HR+/HER2- ABC who received palbociclib + ET.

Results: A total of 1250 patients received ≥ 1 palbociclib dose (1LOT: 901 [72.1%]; ≥ 2LOT: 349 [27.9%]). In the 1LOT group, 563 (62.5%) had received prior (neo)adjuvant treatments: 24.3% ET alone, 26.6% chemotherapy alone, 45.5% ET + chemotherapy, and 3.6% other treatments; both median rwPFS and OS were numerically longer in patients who had received ET alone (30.4 months and not reached, respectively) and had had no prior treatment (23.7 and 53.3 months, respectively) than in patients with prior chemotherapy alone (15.9 and 38.4 months, respectively). In the ≥ 2LOT group, patients with prior ET alone (21.5%; 19.8 months) or chemotherapy alone (16.6%; 15.5 months) in the (neo)adjuvant and/or metastatic setting had numerically longer median rwPFS than those with prior ET + chemotherapy (41.3%; 11.6 months); OS was comparable regardless of prior treatment.

Conclusions: Patients with HR+/HER2- ABC who had received ET alone prior to palbociclib tended to have better clinical outcomes, while those with prior chemotherapy had less clinical benefit.

Trial registration: ClinicalTrials.gov, NCT03280303.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Targeted Oncology
Targeted Oncology 医学-肿瘤学
CiteScore
8.40
自引率
3.70%
发文量
64
审稿时长
>12 weeks
期刊介绍: Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信